Medical Condition News

RSS

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Researchers personalizing cancer treatments for young patients

The aim of personalizing cancer treatments by targeting genomic mutations in the cancer has seen rapid advances in recent years. However, many of these targeted cancer therapies have been more frequently identified for adult patients. Recognizing a need to further explore genomic profiling in pediatric malignancies, the Hugs for Brady Foundation has committed $300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.

11 Dec 2013

Acid-inhibiting medications linked with increased risk for vitamin B12 deficiency

Use for 2 or more years of proton pump inhibitors and histamine 2 receptor antagonists (two types of acid-inhibiting medications) was associated with a subsequent new diagnosis of vitamin B12 deficiency, according to a study appearing in the December 11 issue of JAMA.

11 Dec 2013

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful intramuscular injection for more than 40 years, research suggests.

11 Dec 2013

Experimental compound reduces joint inflammation in animal models of rheumatoid arthritis

An experimental compound synthesized and developed by scientists from the Florida campus of The Scripps Research Institute has the capacity to significantly reduce joint inflammation in animal models of rheumatoid arthritis, an autoimmune disease that affects more than two million Americans.

11 Dec 2013

Budget cuts, years-long flat funding can delay research into effective treatments for cancer

Research advances that have come to fruition over the past year demonstrate extraordinary progress in the fight against cancer, according to a new report released today by the American Society of Clinical Oncology. The report stresses, however, that recent budget cuts and years-long flat funding can only delay efforts to translate research into effective treatments for millions of individuals with cancer.

11 Dec 2013

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.

11 Dec 2013

Broad Medical Research Program, Crohn's & Colitis Foundation of America to merge together

The Broad Medical Research Program, which funds innovative early-stage research into inflammatory bowel disease, will merge with the Crohn's & Colitis Foundation of America, the two organizations announced today.

11 Dec 2013

CatchMyPain App for patients suffering from chronic pain

Pain management as an independent medical field has been significantly growing during the last few decades. Doctors and clinics specialize in the treatment of pain in general and chronic pain specifically. These specialists often suggest using a pain diary to track the pain, see its development and adjust the treatment accordingly. CatchMyPain is an electronic version of such a pain diary and a great solution for patients suffering from chronic pain.

11 Dec 2013

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate for Alzheimer's disease.

11 Dec 2013

GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma.

11 Dec 2013

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana.

11 Dec 2013

Study looks at brain imaging data in veterans who suffered combat-related head injuries

In preliminary findings, Saint Louis University researchers report that veterans who suffered blast injuries have changes in brain tissue that are still apparent in images years after the blast. The data, presented at the annual meeting of the Radiological Society of North America, represents a small but intriguing look at brain imaging in those who suffered combat-related head injuries.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Merck provides update on MK-8931 investigational oral therapy for Alzheimer’s disease

Merck, known as MSD outside the United States and Canada, today provided an update on the development program for MK-8931, a novel investigational oral β-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor.

11 Dec 2013

EyeTechCare's new EyeOP1 device now available in six more French health care facilities

EyeTechCare SA, which develops non-invasive therapeutic medical devices for the ophthalmology market based on the use of ultrasound, today announces that six more health care facilities in France now have the new EyeOP1 device.

11 Dec 2013

New review calls for action to reduce illness and death from silica exposure at work

A new review highlights new developments in understanding the health effects of silica, and calls for action to reduce illness and death from silica exposure at work, including stronger regulations, heightened awareness and prevention, and increased attention to early detection of silicosis and lung cancer using low dose CT scanning.

11 Dec 2013

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene today announced that data from the FIRST (Frontline Investigation of lenalidomide and dexamethasone vs. standard thalidomide) trial was presented on Sunday 8 December, during the Plenary Scientific Session at the 55th American Society Hematology annual meeting in New Orleans. FIRST (MM-020/IFM 07-01) a phase III, multi-centre study in patients newly diagnosed with multiple myeloma and ineligible for stem cell transplant, included 72 patients from the UK.

11 Dec 2013

Genzyme granted Priority Review for Cerdelga investigational oral therapy for Gaucher disease

Genzyme, a Sanofi company, announced today that the Food and Drug Administration (FDA) has granted a six-month Priority Review designation to its New Drug Application (NDA) for Cerdelga™ (eliglustat), an investigational oral therapy for adult patients with Gaucher disease type 1.

11 Dec 2013

CPAP treatment effective in patients with obstructive sleep apnea and hypertension

Among patients with obstructive sleep apnea and hypertension that requires 3 or more medications to control, continuous positive airway pressure treatment for 12 weeks resulted in a decrease in 24-hour average and diastolic blood pressure and an improvement in the nocturnal blood pressure pattern, compared to patients who did not receive CPAP, according to a study appearing in the December 11issue of JAMA.

11 Dec 2013

Medical Condition News

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Researchers personalizing cancer treatments for young patients

Acid-inhibiting medications linked with increased risk for vitamin B12 deficiency

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Experimental compound reduces joint inflammation in animal models of rheumatoid arthritis

Budget cuts, years-long flat funding can delay research into effective treatments for cancer

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

Broad Medical Research Program, Crohn's & Colitis Foundation of America to merge together

CatchMyPain App for patients suffering from chronic pain

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

GW Pharmaceuticals receives U.S. patent for treating glioma

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Study looks at brain imaging data in veterans who suffered combat-related head injuries

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Merck provides update on MK-8931 investigational oral therapy for Alzheimer’s disease

EyeTechCare's new EyeOP1 device now available in six more French health care facilities

New review calls for action to reduce illness and death from silica exposure at work

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Genzyme granted Priority Review for Cerdelga investigational oral therapy for Gaucher disease

CPAP treatment effective in patients with obstructive sleep apnea and hypertension

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News